NCT07524959

Antagonism of Neostigmine in Continuous Infusion of Mivacurium

Antagonism of Neostigmine in Continuous Infusion of Mivacurium: a Randomised Controlled Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anesthesia was investigated, and the appropriate time point of antagonism was explored.

Detailed description

Mivacurium is currently the shortest-acting benzylisoquinoline nondepolarizing muscular relaxant in clinical practice, which is suitable for short surgery. Its continuous infusion can also be used in medium-term surgery with uncertain operation time, which can accelerate the recovery of postoperative muscle relaxation. Whether continuous infusion of mivacurium requires antagonism and the appropriate time point of antagonism is controversial.

Conditions

• Neuromuscular Blocking Agents

Interventions

Type	Name	Description
DRUG	Neostigmine	Administer neostigmine at a dose of 0.04 mg/kg (combined with 0.02 mg/kg atropine)

Timeline

• Start date: 2026-05-01
• Primary completion: 2026-07-20
• Completion: 2026-07-29
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: China